CLL Global Research Foundation presentation di... - CLL Support
CLL Global Research Foundation presentation discusses research news from ASH 2023, ongoing clinical trials and latest treatment approaches
You need to be a member of this community to see this post.
Read more about...
4 Replies
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
Dr. Lamanna and Dr. Thompson Discuss what is CLL, the latest research and planning for treatment
Hello all,
Wanted to make you aware of Patient Power's morning session replay from recent town...
OncLive 9 CLL Videos - Optimizing the Treatment of CLL With Novel Therapies and more Take-home messages from ASH 2021
The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for...
Reflections from Cardiff, news of CLL research and the changing trials landscape
Hi everyone
After reflecting on yesterday's Cardiff CLLSA patient meeting and...
Zanubrutinib vs. Ibrutinib Patient Power Video by Dr. Jennifer Brown MD PHD
In this Patient Power video - Dr. Brown is very clear about the advantages of Zanubrutinib over...
Venetoclax is being considered for approval in Australia - Aussies, please support this application! Closing date 8th Feb
Venetoclax for relapsed/refractory CLL will be considered at the next Pharmaceutical Benefits...
Related Posts
- YABTKi or Yet Another BTK inhibitor - an A to Z list of Bruton's Tyrosine Kinase Inhibitors and Degraders following ibrutinib's success
Triplet Regimen Shows Promise in CLL -Zanubrutinib, obinutuzumab, & venetoclax combo achieves rapid undetectable MRD -MedPageToday -07/07/20
BTK inhibitors for the treatment of CLL - the current state of play of 'brutinibs'
Dr. Fauci shares his recommendation that immunosuppressed patients with blood cancers, like us, get the vaccine, because some immunity is be
Early results of the Pirtobrutinib, Obinituzumab, Venetoclax trial I'm on have just been published
